Adial Pharmaceuticals (ADIL) Change in Accured Expenses (2017 - 2026)

Adial Pharmaceuticals has reported Change in Accured Expenses for 10 years, with the latest figure at $194802.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 139.79% year-over-year to $194802.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14321.0 (up 137.52% YoY) and the FY2025 annual result came in at $405077.0, up 175.93% from the prior year.
• Change in Accured Expenses rose to $194802.0 in Q1 2026 per ADIL's latest filing, from -$42934.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $857099.0 in Q2 2022 and troughed at -$1.7 million in Q3 2022.
• A 5-year average of -$133618.1 and a median of $23181.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 6466.22% in 2022, then soared 179.27% in 2025.
• Over 5 years, Change in Accured Expenses stood at $110082.0 in 2022, then sank by 37.2% to $69133.0 in 2023, then tumbled by 66.47% to $23181.0 in 2024, then tumbled by 285.21% to -$42934.0 in 2025, then jumped by 553.72% to $194802.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $194802.0, -$42934.0, and -$218786.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.